BPC May 06 update

​Esperion ESPR shares up 12% on NDA acceptance; Catalyst CPRX -44% after-hours on competitor approval

Price and Volume Movers

Esperion (Nasdaq: ESPR) shares closed up 12% following news the FDA has accepted both New Drug Applications for bempedoic acid and the bempedoic acid / ezetimibe combination, for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). The PDUFA date for bempedoic acid is set for February 21, 2020, while the PDUFA date for bempedoic acid / ezetimibe combination is February 26, 2020. Investors reacted positively on news that the FDA does not intend to hold an advisory committee meeting to discuss the applications.

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) announced that its second Phase 3 trial of of RVL-1201 for the treatment of ptosis (droopy eyelid), met the primary endpoint, demonstrating a statistically significant improvement in the visual field of patients that were administered our once-daily drop. The company intends to submit a New Drug Application (NDA) to the FDA in 3Q 2019. Shares are trading up 46% to $5.65 after hours.

Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares have slid 44% after hours to $3.45 on news the FDA granted approval of Ruzurgi to Jacobus Pharmaceutical Company, Inc. Ruzurgi is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age. This is the first FDA approval of a treatment specifically for pediatric patients with LEMS. The only other treatment approved for LEMS is approved for use in adults and is marketed by Catalyst Pharmaceuticals.

GW Pharmaceuticals plc (NASDAQ: GWPH) announced positive data in its Phase 3 clinical trial of Epidiolex in the treatment of seizures associated with Tuberous Sclerosis Complex (TSC), a form of childhood-onset epilepsy. The trial met its primary endpoint, which was the reduction in seizure frequency compared to baseline of the Epidiolex 25 mg/kg/day dose group vs placebo (p=0.0009). Shares are trading up 6% to $190.00 after hours.

Cytokinetics, Incorporated (Nasdaq: CYTK) announced that its Phase 2 FORTITUDE-ALS trial of reldesemtivof in ALS did not meet the primary endpoint of change from baseline in slow vital capacity (SVC) after 12 weeks of dosing (p=0.11). Shares, however, closed up 7% to $9.48, with the company pushing clinically meaningful data following post-hoc analysis to continue development.

Athenex, Inc. (NASDAQ: ATNX) announced the sale of its common stock in a private placement with three institutional investors, Perceptive Advisors, Avoro Capital Advisors and OrbiMed, for gross proceeds of $100m. Shares closed up 28% to $12.99.


Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume


Ovid Therapeutics Inc. (OVID): $2.14; +17%.

Regulus Therapeutics Inc. (RGLS): $1.26; +17%.

ImmunoGen, Inc. (IMGN): $3.30; +15%.

Checkpoint Therapeutics, Inc. (CKPT): $4.72; +13%.

Zynerba Pharmaceuticals, Inc. (ZYNE): $12.76; +11%.


NGM Biopharmaceuticals, Inc. (NGM): $14.88; -6%.

Adaptimmune Therapeutics plc (ADAP): $4.37; -6%.

Minerva Neurosciences, Inc. (NERV): $7.19; -5%.

Alnylam Pharmaceuticals, Inc. (ALNY): $74.08; -4%.

Novan, Inc. (NOVN): $1.17; -4%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

ABUS – Arbutus Biopharma Corporation
Hepatitis B (HBV)

Phase 1 Phase 1 data due July 2019.
$135.8 million

ADAP – Adaptimmune Therapeutics plc
Synovial sarcoma or myxoid/round cell liposarcoma (MRCLS)

Phase 2 Phase 2 trial to be initiated later in 2019.
$366.5 million

AXSM – Axsome Therapeutics Inc.

Phase 3 Phase 3 top-line data due 2H 2019.
$865.9 million

CCXI – ChemoCentryx Inc.
Avacopan - CCX168 (ADVOCATE)
Associated vasculitis (AAV)

Phase 3 Phase 3 data due 4Q 2019.
$479.5 million

CRIS – Curis Inc.
Solid Tumors and Lymphomas

Phase 1 Phase 1 mesothelioma data due 2H 2019.
$81.6 million

CYTK – Cytokinetics Incorporated
Reldesemtiv (CK-2127107) - FORTITUDE-ALS
Amyotrophic lateral sclerosis (ALS)

Phase 2 Phase 2 data presented at AAN, May 5, 2019, failed to meet primary endpoint.
$639 million

EPZM – Epizyme Inc.
Epithelioid Sarcoma

NDA Filing NDA filing announced May 30, 2019.
$1.2 billion

GWPH – GW Pharmaceuticals Plc
Tuberous Sclerosis Complex

Phase 3 sNDA filing due 4Q 2019.
$5.2 billion

NERV – Minerva Neurosciences Inc
Roluperidone (MIN-101)

Phase 3 Phase 3 data due 4Q 2019.
$252.5 million

OSMT – Osmotica Pharmaceuticals plc

NDA Filing Phase 3 data May 6, 2019 met primary endpoint. NDA filing due 3Q 2019.
$190.1 million

PFE – Pfizer Inc.
Transthyretin amyloid cardiomyopathy (ATTR-CM)

Approved FDA approval announced May 6, 2019.
$237.7 billion

PLX – Protalix BioTherapeutics Inc. (DE)
Pegunigalsidase alfa (PRX-102) - BRIGHT
Fabry disease

Phase 3 Phase 3 completion of enrolment announced June 17, 2019.
$60.7 million

RARE – Ultragenyx Pharmaceutical Inc.
Ornithine Transcarbamylase (OTC) Deficiency

Phase 1/2 Phase 1/2 third cohort data due mid-2019.
$3.4 billion

SVRA – Savara Inc.
Molgradex - IMPALA
Autoimmune pulmonary alveolar proteinosis (PAP)

Phase 3 Phase 3 data June 12, 2019 did not meet primary endpoint.
$99.2 million